Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Steroid Biochem Mol Biol ; 109(3-5): 336-43, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18430567

RESUMO

Steroid hormones activate target cells through specific receptors that discriminate among ligands based upon recognition of distinct structural features. For most known steroids, membrane and nuclear receptors co-exist in many target cells. However, while the structure of the nuclear receptors and their function as transcriptional activators of specific target genes is generally well understood, the identity of the membrane receptors remains elusive. Using pharmacological and biochemical approaches, we are beginning to characterize receptors for glucocorticoids and anabolic-androgenic steroids in male rat liver membranes. Male rat liver endoplasmic reticulum contains two steroid binding sites which are functionally related and associated with a 90-134 kDa oligomeric protein: (1) the low-affinity glucocorticoid binding site (LAGS), composed at least in part of two peptides (37 and 53 kDa) that bind glucocorticoids and (2) the stanozolol binding protein (STBP), composed at least in part of three peptides (22, 31, and 55 kDa) that bind the synthetic androgen stanozolol. These steroid binding proteins have many properties different from those of classical nuclear receptors, with the salient differences being a failure to recognize "classical" ligands for nuclear receptors together with marked differences in biochemical properties and physiological regulation. The mechanism of interaction of glucocorticoids with the LAGS can be clearly distinguished from that with STBP. Moreover, STBP shows an extremely narrow pharmacological profile, being selective for ST and its analog, danazol, among more than 100 steroids and non-steroidal compounds that were assayed, including those that are able to displace glucocorticoids from the LAGS. The level of LAGS activity undergoes dramatic variations following changes from the physiological serum levels of thyroid hormones, glucocorticoids, GH, vitamin A, and E2. However, neither thyroid hormones nor GH have a critical role on STBP activity. The STBP is functionally related to LAGS. We have suggested a novel mechanism for STBP whereby membrane-associated glucocorticoid binding activity is targeted by stanozolol (and 16beta-hydroxylated stanozolol): stanozolol modulates glucocorticoid activity in the liver through negative allosteric modulation of the LAGS resulting in an effective increase in classical GR-signaling by increasing glucocorticoid availability to the cytosolic GR.


Assuntos
Membrana Celular/metabolismo , Glucocorticoides/metabolismo , Hormônios Esteroides Gonadais/metabolismo , Fígado/citologia , Fígado/metabolismo , Hormônios Hipofisários/metabolismo , Animais , Sítios de Ligação
2.
Clín. investig. arterioscler. (Ed. impr.) ; 19(3): 136-142, mayo 2007. ilus, tab
Artigo em Es | IBECS | ID: ibc-053994

RESUMO

Introducción. La presentación prematura de la enfermedad coronaria es relativamente frecuente, pero sus factores predictores todavía no se conocen bien. Método. Analizamos los factores de riesgo en varones canarios: 515 pacientes menores de 51 años, con enfermedad coronaria documentada, y 436 controles mayores de 56 años, sin enfermedad. Resultados. La serie presenta una elevada prevalencia de factores de riesgo; el 98% de los pacientes y el 93% de los controles tenían al menos un factor de riesgo cardiovascular (p < 0,001). Encontramos diferencias significativas (p < 0,001) en la frecuencia de antecedente familiar de enfermedad prematura (35% pacientes y 15% controles), tabaquismo (85% pacientes y 76% controles) y dislipemia (78% pacientes y 53% controles) superior en pacientes. La hipertensión arterial resultó el factor más prevalente en controles (51% pacientes y 66% controles; p < 0,001). Pese al tratamiento con estatinas, los pacientes presentaban índices aterogénicos (triglicéridos/colesterol unido a lipoproteínas de alta densidad [cHDL]) más elevados que los controles (promedio 5,39 pacientes y 4,10 controles; p < 0,001). La enfermedad coronaria se adelantaba 2 años en pacientes con índices aterogénicos superiores a 5,5 (48,2 años con índice bajo y 46,6 años con índice aterogénico alto; p < 0,013). El análisis multivariante de pacientes normotensos seleccionó índice aterogénico superior a 4 (p < 0,004; odds ratio (OR) = 1,263-3,617), antecedentes familiares de enfermedad coronaria prematura (p < 0,013; OR = 1,154-3,980) y dislipemia (p < 0,001; OR = 1,936-5,346), como principales predictores de enfermedad coronaria prematura. Conclusiones. A pesar de su juventud, la prevalencia de factores de riesgo en pacientes canarios masculinos es muy elevada. El índice aterogénico resulta una herramienta muy útil y relativamente independiente de las estatinas, para detectar los sujetos con riesgo de presentar enfermedad coronaria prematura (AU)


Introduction. Although premature coronary heart disease (CHD) is relatively frequent, the factors predicting its development are still poorly defined. Method. We analyzed risk factors and lipid profiles in a series of men from the Canary Islands (Spain): 515 patients aged less than 51 years with documented CHD and 436 elderly controls aged more than 56 years without CHD. Results. Most patients and controls had at least one major risk factor (98% of patients and 93% of controls; P<.001). We found significant differences (P<.001) in the prevalence of a family history of premature CHD (35% of patients and 15% of controls), smoking (85% of patients and 76% of controls), and dyslipidemia (78% of patients and 53% of controls). Only hypertension was more common among controls (51% of patients and 66% of controls; P<.001). Despite statin therapy, patients showed a higher atherogenic index (triglycerides/high density lipoprotein HDL-cholesterol [HDL-c] ratio) than controls, the mean index being 5.39 in patients and 4.10 in controls (P<.001). In normotensive patients the multivariate analysis shows as the major predictors of premature coronary disease: atherogenic index higher than 4 (P<.004, OR = 1.154-3.980), and dislypidemia (P<.001, OR = 1.936-5.346). Conclusion. Despite their youth, male patients with CHD in the Canary Islands have a very high prevalence of risk factors. The atherogenic index is a highly useful tool and is relatively independent of the effects of statin therapy in detecting individuals at risk for premature CDH (AU)


Assuntos
Masculino , Adulto , Pessoa de Meia-Idade , Humanos , Doença das Coronárias/epidemiologia , Hipertensão/complicações , Indicador de Risco , Doença das Coronárias/etiologia , Lipoproteínas HDL/imunologia , Colesterol/imunologia , Fatores de Risco , Hipertensão/imunologia
3.
Oncología (Barc.) ; 23(9): 439-445, sept. 2000. tab, graf
Artigo em Es | IBECS | ID: ibc-10358

RESUMO

Propósito: La incidencia y mortalidad por cáncer de mama en Gran Canaria es una de las más altas de España. En este estudio analizamos las características epidemiológicas y clínico-patológicas de un grupo de pacientes con diagnóstico de cáncer de mama. Material y métodos: Se estudiaron 474 pacientes con cáncer de mama, diagnosticadas y tratadas entre diciembre de 1990 y marzo de 1996, en los dos Hospitales Generales de nuestra Provincia. Se confeccionó una base de datos y los análisis estadísticos realizados fueron, fundamentalmente, medidas de tendencia central y medidas de dispersión. Resultados: La edad media y mediana fue de 60 años. El grupo entre 56 y 60 años representó el 17,7 por ciento. El 83,8 por ciento de las neoplasias se detectaron por autopalpación y el 9,3 por ciento por mamografía. El 8,9 por ciento tenían antecedentes familiares de carcinoma de mama en primer grado. Se practicó mastectomía radical modificada en el 78,1 por ciento y cirugía conservadora en el 19,4 por ciento de los casos. Conclusiones: En nuestra serie, un alto porcentaje de tumores 83,8 por ciento fueron palpables precisando en el 78,1 por ciento la realización de mastectomía radical modificada (AU)


Assuntos
Neoplasias da Mama/epidemiologia , Neoplasias da Mama/etiologia , Europa (Continente)/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA